HEALTH OF WOMAN. 2015.6(102):89–93; doi 10.15574/HW.2015.102.89 
 

Clinical and epidemiological aspects parvovirusnoyi-B19 infection during pregnancy (clinical research) 
 

Bondarenko N. P., Lakatosh V. P., Belaya V. V., Aksonova A. V.

A.A. Bogomolets National Medical University, Kiev

Perinatal center, Kiev 
 

Parvovirus B19 is a widespread infection that affects about 1.6% (р<0.05) of expectant women with normal pregnancy. It was found that the frequency of seropositivity for parvovirus in pregnant women is 43.6% (there are only specific IgG). In 12.4% of cases among inspected women with suspicion on a parvovirus infection found out IgM to the parvovirus В19 during pregnancy. The rest of the women (44%) did not meet with parvovirus В19 and have a potential risk to be infected. The annual frequency of educed initially infected pregnant during the period from 2010 to 2014 years was 0.8–2.7%. Epidemic periods are repeated every 3–4 years. The risk of infection is increased in case of contact with young children. The most commonly infected mothers with many children are exposed to, as well as workers of kindergartens and schools. Parvovirus infection is characterized by seasonality, cases of infections are more common in the off-season, especially dangerous infections for February-March-April, the share of seasonal incidence for the period February-May is about 58.5%. The frequency of asymptomatic infections in pregnant women is 4.8%. The most common intrauterine symptomathy of the fetus in case of infected mother is a non-immune hydrops (11.8%). Acute symptomatic parvovirus infection in the mother during the I and II trimesters of pregnancy in 100% has negative consequences for the fetus. 
 

Key words: parvovirus B19, pregnancy, non-immune fetal hydrops, spontaneous miscarriage, enzyme immunoassay (EIA), class M immunoglobulins (IgM) to parvovirus B19, class G specific immunoglobulins (Ig G). 
 

REFERENCES

1. Матвеев ВА, Прощаева НВ, Самойлович ЕО, Ермолович МА. 2008. Клинико-лабораторная характеристика В19-парвовирусной инфекции. Инфекционные болезни 6;3:33–37.

2. Савилов ЕД, Мамонтова ЛМ, Астафьев ВА, Жданова СН. 2004. Применение статистических методов в эпидемиологическом анализе. М, МЕДпресс-информ:112.

3. Brown T, Anand A, Ritchie LD, Clewley JP, Reid TM. 1984. Intrauterine parvovirus infection associated with hydrops fetalis. Lancet 2:1033.

4. Chiasaka H, Morita,Yaegashi N, Sugamura K. 2003, Nov–Dec. Parvovirus B19 and the pathogenesis of anaemia. Rev Med Virol. 13(6):347–59.

5. Cossart YE, Field AM, Cant B, Widdows D. 1975. Parvovirus-like particles in human sera. Lancet:72–73.

6. De Jong EP, de Haan TR, Kroes AC et al. 2006, May. Parvovirus B19 infection in pregnancy. J Clin Virol. 36(1):1–7.

7. Ergaz Z, Ornoy A, 2006, May. Parvovirus B19 in pregnancy. Reprod Toxicol. 21(4):421–35.

8. Goff M, 2005, Nov-Dec. Parvovirus B19 in pregnancy. J Midwifery Womens Health 50 (6):536–8.

9. Jin Xu, MD, Thomas C. Raff, MD, Nabil S. Muallem, MD and A. 2003, January–February. George Neubert, MD. Jin Xu Hydrops Fetalis Secondary to Parvovirus B19 Infections. JABFP.16;1:63–68.

10. Lefrere JJ, Maniez-Montreuil M, Morel P et al. 2006, Jul 3. Safety of blood products and parvovirus. Transfus Clin Biol.

11. Servant-Delmas A, Laperche S, Mercier M. Diversite genetique des Erythrovirus humains:200.

12. Seve P, Ferry T, Charhon A, Calvet A, Broussolle C. 2004, Oct. Systemic manifestations of Parvovirus B19 infections. Rev Med Interne. 25(10)740–51.

13. Tohoku J. 2006, Aug. Clinical manifestations and outcomes of parvovirus B19 infection during pregnancy in Japan. Exp Med. 209(4):277–83.

14. Von Kaisenberg CS, Jonat W. 2001, Sep. Fetal parvovirus B19 infection. Ultrasound Obstet Gynecol. 18(3):280–8.

15. Ziyaeyan M, Rasouli M, Alborzi A. 2005, Apr. The seroprevalence of parvovirus B19 infection among to-be-married girls, pregnant women and their neonates in Shiraz, Iran. Jpn J Infect Dis. 58(2):95–7.